IgA Nephropathy δημόσια
[search 0]
Περισσότερα
Download the App!
show episodes
 
Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
  continue reading
 
Loading …
show series
 
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.Από τον Travere Therapeutics
  continue reading
 
Loading …

Οδηγός γρήγορης αναφοράς